2012. isolate. Download Number?S1, TIF file, 0.4 MB mbo006152607sf1.tif (461K) GUID:?5C61F233-9A6D-4FB5-BA11-172BBA5332A4 Number?S2 : Correlation of group 1 antistalk titers and HA inhibition (HAI) titers. The correlations for children (A), for adults (B), and for Bgn the elderly (C) are demonstrated. While antistalk titers and HAI titers correlate well for children, no correlation is definitely observed in the elderly. Adults display an intermediate phenotype. Download Number?S2, TIF file, 0.4 MB mbo006152607sf2.tif (375K) GUID:?4203C1E6-62C3-4F2E-AA77-929C031C3669 Figure?S3 : Stalk-reactive antibody KB2 competes with prevaccination sera from adults (A) and the elderly (B) for stalk binding. The data are demonstrated as areas MM-102 TFA under the curve. Download Number?S3, TIF file, 0.5 MB mbo006152607sf3.tif (559K) GUID:?CDA1C9DE-4447-4846-AE63-43575F15849B ABSTRACT Influenza remains a major global health burden. Seasonal vaccines present safety but can be rendered less effective when the disease undergoes considerable antigenic drift. Antibodies that target the highly conserved hemagglutinin stalk can protect against drifted viruses, and vaccine constructs designed to induce such antibodies form the basis for any universal influenza disease vaccine approach. In this study, we analyzed baseline and postvaccination serum samples of children (6 to 59?weeks), adults (18 to 49?years), and elderly individuals (65 years) who also participated in clinical tests having a recombinant hemagglutinin-based vaccine. We found that baseline IgG and IgA antibodies against the H1 stalk website correlated with the age groups of individuals. Children generally experienced very low baseline titers and did not respond well to the vaccine in terms of making stalk-specific antibodies. Adults showed the highest induction of stalk-specific antibodies, but the seniors experienced the highest complete antibody titers against the stalk. Importantly, the stalk antibodies MM-102 TFA measured by enzyme-linked immunosorbent assay (ELISA) showed neutralizing activity in neutralization assays and safeguarded mice inside a passive-transfer model inside a stalk titer-dependent manner. Finally, we found related patterns of stalk-specific antibodies directed against the H3 and influenza B disease hemagglutinins, albeit at lower levels than those measured against the H1 stalk. The relatively high levels of stalk-specific antibodies in the elderly patients may clarify the previously reported low influenza disease infection rates with this age group. (This study has been authorized at ClinicalTrials.gov under sign up no. “type”:”clinical-trial”,”attrs”:”text”:”NCT00336453″,”term_id”:”NCT00336453″NCT00336453, “type”:”clinical-trial”,”attrs”:”text”:”NCT00539981″,”term_id”:”NCT00539981″NCT00539981, and “type”:”clinical-trial”,”attrs”:”text”:”NCT00395174″,”term_id”:”NCT00395174″NCT00395174.) IMPORTANCE The present study provides evidence that titers of broadly neutralizing hemagglutinin stalk-reactive antibodies increase with age, probably due to repeated exposure to divergent influenza viruses. These relatively high levels of antistalk titers may MM-102 TFA be responsible for lower circulation rates of influenza viruses in older individuals. Our findings suggest that the level of antistalk antibodies is a good surrogate marker for safety against influenza disease infection. In addition, the levels of antistalk antibodies might determine the MM-102 TFA breadth of safety against different drifted strains. Intro Seasonal influenza disease infections cause significant global morbidity and mortality every year (1, 2). In addition, influenza A viruses cause pandemics in irregular intervals. Current influenza disease vaccines are efficacious but are very strain specific and protect against viruses well matched with the vaccine formulation (3). Immunity induced by these standard vaccines is mostly directed to the immuno-dominant globular head website of the hemagglutinin (HA), the major surface glycoprotein of the disease. This part of the HA has a high plasticity and allows the disease to escape the immune response, a mechanism called antigenic drift (4). This trend makes it necessary to upgrade vaccines on a regular (annual) basis (5). Antibodies against the conserved, immuno-subdominant stalk website of the HA are usually not induced to high titers by seasonal influenza disease vaccines (6,C8). However, such antibodies have been shown to be broadly protecting and efficacious against.